BioCryst Pharmaceuticals Inc (BCRX): Net Income
$263.86M
Year ended 2025-12-31
-$384.67M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $263.86M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$88.88M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$226.54M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$247.12M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$184.06M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$182.81M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$108.90M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$101.25M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$65.78M | n/m | 2020-03-13, From 2017-01-01 |
| 2016-12-31 | -$55.14M | n/m | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | -$43.02M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | -$45.19M | n/m | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | -$30.11M | n/m | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | -$39.08M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$56.95M | n/m | 2014-03-10, From 2011-01-01 |
| 2010-12-31 | -$33.85M | n/m | 2013-03-11, From 2010-01-01 |
| 2009-12-31 | -$13.45M | n/a | 2012-03-06, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $263.86M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $48.89M | n/m |
| Novavax Inc (NVAX) | 2025-12-31 | $440.30M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $181.86M | +147.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $316.89M | -28.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.93M | -25.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$66.42M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$35.51M | n/m |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$2.82B | n/m |
Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗